Clinical Research

PAD patients face greater risk of death, complications after a heart attack

PAD and CLI patients who show signs of coronary heart disease may benefit from early treatment, according to a new study of nearly 4 million hospitalizations. 

artificial intelligence consultation

New research offers reminder of why ChatGPT should not be used for second opinions

Although these tools have proven themselves valuable in numerous settings, they must be used with caution, especially by patients and nonradiologist providers who may be seeking clarification on imaging reports. 

Thumbnail

Mindfulness audio eases symptoms for prostate cancer patients during radiation therapy

Experts signaled optimism for how their findings could benefit men who might be reluctant to seek support while battling cancer. 

radiation oncology therapy treatment

Edema scores can help predict the aggressiveness of breast cancer

Applying an edema classification system to preoperative MRI exams provides insight into whether patients' breast cancer will spread.

Confirmed: AFib ablation more beneficial for patients with HFrEF than those with HFpEF

Researchers explored data from nearly 2,500 AFib ablation patients, sharing their findings in JAMA Cardiology.

An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.

Cardiologists share update after world’s first implant of new optimizer device for tricuspid regurgitation

The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.

Thumbnail

Could diamond dust replace gadolinium in MRI contrast agents?

An accidental discovery could have future implications for the material makeup for MRI contrast media.

Thumbnail

Statin therapy may help HFpEF patients lower their risk of death, heart attack or stroke

All participants were free of ASCVD and had no history of statin use at the start of the study.